Cargando…

Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery

BACKGROUND: Nearly 30% of stage IA non-small-cell lung cancer patients eventually die of recurrence or metastasis. This study aimed to predict stage IA lung adenocarcinoma (LADC) patients who underwent radical resection with a high risk of recurrence or metastasis. METHODS: Information on clinicopat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Lu, Pang, Chong, Xu, Fei, Yang, Guangjian, Xu, Haiyan, Wang, Changli, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732172/ https://www.ncbi.nlm.nih.gov/pubmed/33324099 http://dx.doi.org/10.2147/CMAR.S286503

Ejemplares similares

Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma
por: Yang, Lu, et al.
Publicado: (2020)

Development and validation of a nomogram based on preoperative variables for predicting recurrence‐free survival in stage IA lung adenocarcinoma
por: Xu, Jiaxi, et al.
Publicado: (2023)

HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1
por: Kumagai, Toru, et al.
Publicado: (2018)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yang, Yaning, et al.
Publicado: (2021)

Establishment and validation of a nomogram model for predicting postoperative recurrence-free survival in stage IA3 lung adenocarcinoma: a retrospective cohort study
por: Yu, Shaobin, et al.
Publicado: (2022)

Survival after curative resection for stage I colorectal mucinous adenocarcinoma
por: Huang, Liang, et al.
Publicado: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Role of breath-hold lung PET in stage IA pulmonary adenocarcinoma
por: Cheng, Zhaoping, et al.
Publicado: (2023)

Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma
por: Zhang, Jie, et al.
Publicado: (2017)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China
por: Pi, Can, et al.
Publicado: (2018)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Segmentectomy or Wedge Resection in Stage IA Lung Squamous Cell Carcinoma and Adenocarcinoma?
por: Li, Guoshu, et al.
Publicado: (2021)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
por: Su, Hang, et al.
Publicado: (2021)

Nomograms for intraoperative prediction of lymph node metastasis in clinical stage IA lung adenocarcinoma
por: Li, Feng, et al.
Publicado: (2023)

Solid component ratio influences prognosis of GGO-featured IA stage invasive lung adenocarcinoma
por: Sun, Fenghao, et al.
Publicado: (2020)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma
por: Kim, Yeseul, et al.
Publicado: (2023)

Fertility-Sparing Treatment in Young Patients With Grade 2 Presumed Stage IA Endometrioid Endometrial Adenocarcinoma
por: Yu, Mei, et al.
Publicado: (2020)

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
por: Xu, Fei, et al.
Publicado: (2020)

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma
por: Nie, Yunqiang, et al.
Publicado: (2017)

Intrapulmonary lymph node metastasis is common in clinically staged IA adenocarcinoma of the lung
por: Zhang, DengGuo, et al.
Publicado: (2018)

Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

Effects of a ground-glass opacity component on the recurrence and survival of pathological stage IA3 lung adenocarcinoma: a multi-institutional retrospective study
por: Xu, Shao-Jun, et al.
Publicado: (2023)

Oncologic and obstetric outcomes after conization for adenocarcinoma in situ or stage IA1 cervical cancer
por: Wang, Xiaoyu, et al.
Publicado: (2020)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
por: Xu, Hui, et al.
Publicado: (2020)

Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients
por: Lv, Tangfeng, et al.
Publicado: (2017)

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
por: Sun, Yan, et al.
Publicado: (2014)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

Predictive value of radiological features on spread through air space in stage cIA lung adenocarcinoma
por: Zhang, Zhenrong, et al.
Publicado: (2020)

Sublobectomy for stage IA1‐2 invasive lung adenocarcinoma with consolidation tumor ratio ≤ 0.25
por: Qi, Yi‐Fan, et al.
Publicado: (2022)

Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study
por: Zhang, Yuchao, et al.
Publicado: (2020)

Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ddn4jjine0aumd2e8g8no13ghj